

CURRICULUM VITAE

Name: Michel REVEL

Date of Birth: August 20, 1938

Place of Birth: Strasbourg, France

Family Status: Married, Dr Claire B. Revel, Ph.D.
Children: Dr Ariel A. Revel, M.D., Gynecologist, IVF
Mr Sammy T. Revel, B.Sc., Israeli Diplomat
Dr Shoshana T. Vilc-Revel, M.D., Pediatric Oncology

Nationality Israeli

Education:

1959 B.Sc. - Biology, University of Strasbourg, France
1963 M.D. - Medical School University of Strasbourg, France
1963 Ph.D. - Biochemistry, University of Strasbourg, France

Present Professional Positions:

Professor at The Weizmann Institute of Science, Rehovot, Israel,
full Professor tenure since 1973 (Biochemistry Department).
Since 1989: Department of Molecular Genetics (Emeritus since 2010)

Chief Scientist, Kadimastem Ltd, Nes Ziona, Israel (Pluripotent Stem cells Medical Applications) 2010-present

Awards:

Merck Award, for Multiple Sclerosis Drug Rebif, 2016
Emet Prize, Life Sciences/Biotechnology 2004
Israel Prize, Medical Research, 1999

Member of Israel Academy of Sciences and Humanities, elected in 2005
Honorary membership of the International Society for Interferon and Cytokine Research, 2002
Chevalier de la Legion d'Honneur (France) 2000
Elected Fellow, New York Academy of Science, 1996
Michael Landau Prize, special Mifal Hapayis award for Biotechnology, Israel 1988
Somach Sachs Award for Chemistry, 1970

Appointments:

Biotechnology & Industry:

Chief Scientist of InterPharm Ltd 1990- 2005, (Advisor 1979-1990)

Member, Israel National Council for Research and Development- Molmop (2004-2010)
Chairman, National Israel Steering Committee for Biotechnology, 1999-2001 (Member 1989-2001).
Chairman, Board of Directors, Miles-Yeda, Ness-Ziona, Israel, 1976-1979
Member, Board of Directors, Inter-Yeda, Ness-Ziona, Israel, 1979-1987
Scientific Advisor, Ares-Serono Corporation, 1986- to date
Member, Biotechnology Commission, Israel Nat.Council for Res. and Devpt, 1988
Member, Israel National Committee for Medical Research, 1989-1993

Bioethics:

Chairman, Israel National Bioethics Council (2004-2012)
 Member Rapporteur, UNESCO International Committee of Bioethics (1993-2006)
 Chairman, Bioethics Advisory Committee of the Israel National Academy of Sciences and Humanities (1999- 2004). Member 1999-to date.
 Editor, Bioethics Website of the Israel National Academy of Sciences and Humanities
<http://www.academy.ac.il/bioethics/index.html> (webmaster Dr Ilana Schmidt-Hopfeld)
 Board Chairman, International Center for Health, Law and Ethics, Haifa University
 Member, National Helsinki Committee for Genetic Research in Human Beings, Israel Health Ministry
 Member, Commission on the Status of the Human Embryo, Israel Health Ministry

International Scientific Bodies:

Member, EMBO: European Molecular Biology Organization (since 1974)
 Member, HUGO: Human Genome Organization (since 1990)
 Member, ISICR: International Society for Interferon & Cytokine Research (since 1983)
 Council, International Society for Interferon Research (1983-1988)
 Member, Societe de Chimie Biologique, France
 Member, Israel Biochemical Society
 Fellow, New York Academy of Science (since 1996)
 Scientific Committee, Institut d'Immunologie INSERM, Marseilles, France (1986-1989)
 Scientific Committee, German-Israel Cancer Research (DKFZ, 1993-2003)

Editorial Boards

European Journal of Biochemistry, 1977-1982
 Molecular Biology Reports, 1975-1980
 Interferon, Academic Press (book series) 1979-1987
 Journal of Interferon Research, 1979-1995
 Journal of Antiviral Research, until 1987
 Journal of General Virology, until 1987
 Nucleic Acids Research, 1986-1989
 Cytokines, 1989-2010

Previous Professional Positions:

- 1958-1963 Assistant, Institut de Chimie Biologique (Prof. P. Mandel)
Faculte de Medecine, Universite de Strasbourg, France
- 1963-1964 Research Fellow, Dept of Medicine (Prof. H. Hiatt)
Harvard Medical School, Boston, Mass, USA
- 1964-1965 Research Fellow, Dept of Biochemistry (Prof. U.Z. Littauer)
Weizmann Institute of Science, Rehovot, Israel
- 1966-1968 Charge de Recherches CNRS, Service de Physiologie Microbienne
(Prof. F. Gros) Institut de Biologie Physico-Chimique, Paris, France
- 1968-1970 Senior Scientist, Department of Biochemistry,
Weizmann Institute of Science, Rehovot, Israel
- 1970-1973 Associate Professor, Department of Biochemistry,
Weizmann Institute of Science, Rehovot, Israel
- 1973-1975 Professor, Department of Biochemistry,
Weizmann Institute of Science
- 1974-1975 Eleanor Roosevelt Cancer Research Fellow. Visiting Scientist,
Dept of Biology (Prof. F.H. Ruddle) Yale University, New Haven, Conn, USA
- 1975-1989 Professor, Department of Virology, Weizmann Institute of Science
- 1977-1979 Head of Department of Virology, Weizmann Institute of Science
- 1979 Incumbent Siegel Chair of Virology, Weizmann Institute of Science
- 1979-1990 Senior Scientific Advisor, Inter-Yeda Ltd, Rehovot, Israel
- 1980 (Jan-Feb) Visiting Lecturing Professorship, University of California, Riverside, Cal, USA
- 1981-1983 Head of Department of Virology, Weizmann Institute of Science
- 1983 (Jun-Oct) Visiting Professor, Pasteur Institute, Paris, France
- 1985-1987 Head of Department of Virology, Weizmann Institute of Science
- 1987 Eleanor Roosevelt Cancer Research Fellow. Memorial Sloan Kettering Cancer
Center, Dept of Experimental Hematology, New York, NY, USA
- 1989- 2010 Professor, Department of Molecular Genetics (& Virology)
Weizmann Institute of Science
- 1990- 2005: Chief Scientist, InterPharm Laboratories Ltd
Weizmann Industrial Park, Ness Ziona, Israel
- 2010- to date Professor Emeritus , Department of Molecular Genetics,
Weizmann Institute of Science
- 2010- to date Chief Scientist, Kadimastem Ltd, Nes Ziona, Israel

Selected full research articles - Prof. Michel Revel (numbered as in complete listing)

A) Initiation factors of protein synthesis and translation control

18. A factor from *E. coli* required for the translation of natural messenger RNA. Revel M, Gros F. *Biochem Biophys Res Commun* 25:124-132, 1966.
20. Role of a protein factor in the functional binding of ribosomes to natural messenger RNA. Revel M, Herzberg M, Becarevic A, Gros F. *J Mol Biol* 33:231-249, 1968.
21. GTP-stimulated binding of initiator-tRNA to ribosomes directed by f2 bacteriophage RNA. Anderson LS, Dahlberg JE, Bretscher MS, Revel M and Clark BFC. *Nature* 216: 1072-1076, 1968.
22. Function of three protein factors and ribosomal subunits in the initiation of protein synthesis in *E. coli*. Revel M, Lelong JC, Brawerman G, Gros F. *Nature* 219:1016-1021, 1968.
24. Initiation factor requirements for the *in vitro* synthesis of T4 lysozyme. Brawerman G, Revel M, Salser W, Gros F. *Nature* 223:957-958, 1969.
25. Purification of initiator C from *Escherichia coli*: a protein which binds messenger RNA and initiator tRNA to the 30S ribosome. Herzberg M, Lelong JC, Revel M. *J Mol Biol* 44:297-308, 1969.
26. Initiator protein dependent binding of messenger RNA to ribosomes. Greenshpan H, Revel M. *Nature* 224:331-335, 1969.
29. Translation initiation factor C (F2): Selective inactivation of its f-Met-tRNA binding activity which does not affect messenger RNA binding to the 30S ribosome. Groner Y, Herzberg M, Revel M. *FEBS Lett* 6:315-320, 1970.
30. Specificity in the binding of *Escherichia coli* ribosomes to natural messenger RNA. Revel M, Greenshpan H. *Eur J Biochem* 16:117-122, 1970.
31. Fractionation of translation initiation factor B (F3) into cistron-specific species. Revel M, Aviv (Greenshpan) H, Groner Y, Pollack Y. *FEBS Lett* 9:213-217, 1970
32. Role of Initiation factor B (F3) in the preferential translation of T4 late messenger RNA in T4 infected *E. coli*. Pollack Y, Groner Y, Aviv (Greenshpan) H, Revel M. *FEBS Lett* 9: 218-221, 1970.
34. A novel form of initiation factors from *Escherichia coli* which binds formyl methionyl tRNA and GTP: F2-F3 complex. Groner Y, Revel M. *Eur J Biochem* 22:144-152, 1971.
35. Effect of a purified initiation factor F3 (B) on the selection of ribosomal binding sites on phage MS2 RNA. Berissi H, Groner Y, Revel M. *Nature New Biol* 234:44-47, 1971.
36. *E. coli* initiation factors in the binding of ribosomes to RNA. Revel M, Greenshpan H and Herzberg M. *Methods in Enzymology* 20: 261-277, 1971.
37. Protection of *E. coli* ribosomes against streptomycin by purified initiation factors. Lelong JC, Cousin MA, Gros F, Miskin R, Vogel Z, Groner Y, Revel M. *Eur J Biochem.* 27:174-180, 1972.
38. Characterization of cistron specific factors for the initiation of messenger RNA translation in *E. coli*. Groner Y, Pollack Y, Berissi H, Revel M. *FEBS Lett* 21:223-228, 1972.
39. Cistron specific translation control protein in *Escherichia coli*. Groner Y, Pollack Y, Berissi H, Revel M. *Nature New Biol* 239:16-19, 1972.
40. Host subunit of Q β replicase is translation control factor i. Groner Y, Scheps R, Kamen R, Kolakofsky D, Revel M. *Nature New Biol* 239:19-20, 1972.
43. A comparison of the translation of Mengo virus RNA and Globin mRNA in Krebs ascites cell-free extracts. Lebleu B, Nudel U, Falcoff E, Prives C, Revel M. *FEBS Lett* 25:97-103, 1972.
45. *E. coli* initiation factors: Isolation of an IF2-fMet-transfer RNA complex. Groner Y and Revel M. *J. Mol. Biol.* 74, 407410, 1973.
46. Deficiency in initiation factors of protein synthesis induced by phage T7 in *E. coli* F⁺ strains. Scheps R, Zeller H, Revel M. *FEBS Lett* 27:1-4, 1972.
49. IF3-interference factors: protein factors in *Escherichia coli* controlling initiation of mRNA translation. Revel M, Pollack Y, Groner Y, Scheps R, Inouye H, Berissi H, Zeller H. *Biochimie* 55:41-51, 1973.
50. Discrimination messenger RNA by a mammalian translation initiation factor. Nudel U, Lebleu B, Revel M. *Proc. Natl. Acad. Sci USA* 70:2139-2144, 1973.

61. Studies on the lactose operon. The control of DNA-directed in vitro protein synthesis by interference factor α . Kung HF, Morrissey J, Revel M, Spears C, Weissbach H. *J Biol Chem* 250:8780-8784, 1975.
65. Translational discrimination of 'capped' and 'non-capped' mRNA: inhibition of series of chemical analogs of m7GpppX. Canaani D, Revel M, Groner Y. *FEBS Lett* 64:326-331, 1976.
- Review: Post-transcriptional and translational controls of gene expression in eukaryotes. Revel M and Groner Y. *Annual Review of Biochemistry* 47: 1079-1126, 1978.

B) Interferon: Molecular Mechanism of action

44. Interferon inhibits Mengo virus RNA and hemoglobin mRNA translation in cell free extracts of L cells. E. Falcoff, B. Lebleu, R. Falcoff and M. Revel. *Nature New Biol.* 240, 145-148, 1972.
48. Correlation between the antiviral effect of interferon treatment and the inhibition of in vitro mRNA translation in non-infected L cells. Falcoff. R, Lebleu B and Revel M. *J. Virol.* 12, 421-430, 1973.
56. Effects of interferon on hemoglobin synthesis and leukemia virus production in Friend cells. Lieberman D, Voloch Z, Aviv H and Reve M. *Molec. Biol. Rep.* 1, 447-451, 1974.
57. Blocks in elongation and initiation of protein synthesis induced by interferon treatment in mouse L cells. Content J, Lebleu B, Nudel U, Zilberstein A, Berissi H, Revel M. *Eur J Biochem* 54:1-10, 1975.
63. Antibodies to a cell surface component coded by chromosome 21 inhibit interferon's action. M. Revel, D. Bash and F.H. Ruddle. *Nature* 260: 139-141, 1976.
67. Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L cells. A. Zilberstein, P. Federman, L. Shulman and M. Revel. *FEBS Letts.* 68, 119-124, 1976.
70. Inhibition of viral protein synthesis in monkey cells treated by interferon late after SV40 infection. Yakobson E, Prives C, Hartman J, Winocour E and Revel M. *Cell* 12: 73-81, 1977.
76. Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase. A Zilberstein, A. Kimchi, A. Schmidt and M. Revel. *Proc. Natl Acad. Sci USA* 75, 4734-4738, 1978.
81. Reversal of interferon-induced block in of protein synthesis by eukaryotic translation initiation factor 2. R. Kaempfer, R. Israeli, R. Rosen, S. Knoller, A. Zilberstein, A. Schmidt and M. Revel. *Virology* 99, 170-173, 1979.
83. The interferon-induced protein kinase PK-I from mouse L cells. Kimchi A, Shulman L and Revel M. *J. Biol.Chem.* 254: 9846-9853, 1979.
84. Differential effects of two interferon-induced translational inhibitors on initiation of protein synthesis. Chernajovsky Y, Kimchi A, Schmidt A, Zilberstein A and Revel M. *Eur.J.Biochem.* 96:35-41, 1979.
86. Kinetics of the induction of three translation regulatory enzymes by interferon. Kimchi A, Shulman L, Schmidt A, Chernajovsky A, Fradin A and Revel M. *Proc. Nat. Acad. Sci. USA* 76: 3208-3212, 1979.
87. An interferon-induced phosphodiesterase degrading (2'-5') oligo isoadenylate and the CCA terminus of tRNA. Schmidt A, Chernajovsky Y, Shulman L, Federman P, Berissi H and Revel M. *Proc. Natl. Acad. Sci. USA* 76: 4788-4792, 1979.
89. Regulation of lymphocyte mitogenesis by (2'-5') oligo-isoadenylate. Kimchi A, Shure H and Revel M. *Nature* 282: 849-851, 1979.
92. An interferon-induced cellular enzyme is incorporated into virions. Wallach D and Revel M. *Nature* 287: 68-70, 1980.

C) Human Interferon- β : Gene cloning, production and medical applications

85. Identification of the translation product of human fibroblast interferon mRNA in reticulocyte lysates. Weissenbach J, Zeevi M, Landau T and Revel M. *Eur. J. Biochem.* 97:1-8, 1979.
94. Two interferon mRNAs in human fibroblasts: in vitro translation and E.coli cloning studies. J. Weissenbach, Y. Chernajovsky, M. Zeevi, L. Shulman, H. Soreq, U. Nir, D. Wallach, M. Perricaudet, P. Tiollais and M. Revel. *Proc. Natl. Acad. Sci. USA*, 77, 7152-7156, 1980.

98. Monitoring of interferon therapy by assay of (2'-5') oligo-isoadenylate synthetase in human peripheral white blood cells. A. Schattner, G. Merlin, D. Wallach, H. Rosenberg, T. Bino, T. Hahn, S. Levin and M. Revel. *J. Interferon Res.* 1, 587-593, 1981.
- 100.** Synthesis of human interferon- β 1 in E.coli infected by a lambda phage recombinant containing a human genomic fragment. Y. Mory, Y. Chernajovsky, S.I. Feinstein, L. Chen, U. Nir, J. Weissenbach, Y. Malpiece, P. Tiollais, D. Marks, M. Ladner, C. Colby and M. Revel. *Eur.J.Biochem.* 120, 197-202, 1981.
101. Assay of an Interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. A. Schattner, D. Wallach, G. Merlin, T. Hahn, S. Levin and M. Revel. *The Lancet* 2, 497-500, 1981.
109. Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. M. Fellous, U. Nir, D. Wallach, G. Merlin, M. Rubinstein and M. Revel. *Proc. Natl. Acad. Sci. USA* 79: 3082-3096, 1982.
110. Preferential effect of interferon- γ on the synthesis of HLA antigens and their mRNAs in human cells. D. Wallach, M. Fellous and M. Revel. *Nature* 299, 833-836, 1982.
129. Intramuscular human interferon- β injections in treatment of condylomata acuminata (genital papilloma warts). A. Schoenfeld, S. Nitke, A. Schattner, D. Wallach, M. Crespi, T. Hahn, H. Levavi, O. Yarden, J. Shoham, T. Doerner and M. Revel. *The Lancet*, 1, 1038-1042, 1984.
- 131. Effective constitutive production of human fibroblast IFN- β by hamster cells transformed with the IFN- β 1. gene fused to an SV40 early promoter.** Y. Chernajovsky, Y. Mory, L. Chen, Z. Marks, D. Novick, M. Rubinstein and M. Revel. *DNA*, 3, 297-308, 1984.
- 138.** Efficient constitutive production of human IFN- γ in Chinese hamster ovary cells. Mory Y, Ben-Barak L, Segev D, Cohen B, Novick D, Fischer DG, Rubinstein M, Kargman S, Zilbertsein A, Vigneron M and Revel M. *DNA* 5: 181-193, 1986.
142. Interferons regulate the in vitro differentiation of multilineage lympho-myeloid stem cells in Hairy Cell leukemias. R. Michalevicz and M. Revel. *Proc. Natl. Acad. Sci. USA*, 84, 2307-2311, 1987.
149. Placebo-controlled trial of topical Interferon in labial and genital Herpes. M. Glezerman, E. Lunenfeld, V. Cohen, I. Sarov, M. Movshovitz, M. Doerner, J. Shoham and M. Revel. *The Lancet*, 1, 150-152, 1988.
- 155.** Cloning of genomic DNA for Tumor Necrosis Factor and efficient expression in CHO cells. J.H. Korn, Y. Mory, A. Zilberstein, H. Holtman, M. Revel and D. Wallach. *Lymphokine Res.*, 7, 349-358, 1988.
156. Recombinant interferon α -C for advanced Hairy cell leukemia; an Israeli multicenter study. D. Aderka, R. Michalevicz, Y. Daniel, Y. Levo, D. Douer, I. Ben-Bassat, B. Ramot, M. Shaklai, M. Prokocimer, A. Berrebi, D. Meytes, H. Rosenbaum, D. Wallach and M. Revel. *Cancer*, 61, 2207-2213, 1988.
157. Interferon-beta induced remission in Hairy Cell Leukemia patient resistant to interferon-alpha. R. Michalevicz, D. Aderka, B. Frisch and M. Revel. *Leukemia Res.*, 12, 845-851, 1988.
- 191.** Antagonism of Interferon-beta on Interferon-gamma inhibition of signal transduction in vitro and reduction of serum IFN-gamma levels in Multiple Sclerosis patients. M. Revel, J. Chebath, M. Mangelus, S. Harroch and G.A. Moviglia. *Multiple Sclerosis*, 1, S5-S11, 1995.
193. Effects of topical Interferon- β on recurrence rates in genital Herpes: A double-blind, placebo-controlled, randomized study. J. Ophir, S. Brenner, R. Bali, S. Kriss-Leventon, Z. Smetana and M. Revel. *J. Interferon Cytok. Res.*, 15: 625-631, 1995.
197. Immunoregulatory effects of IFN- β and interacting cytokines on human vascular endothelial cells. Implications for Multiple Sclerosis and other autoimmune diseases. A. Miller, N. Lanis, S. Shapiro, M. Revel, S. Honigman, and A. Lahat. *J. Neuroimmunol.*, 64: 151-161, 1996.
202. Incidence of antibodies to Interferon- β in patients treated with recombinant human Interferon- β 1a from mammalian cells. A. Abdul-Ahad, A. Galazka, M. Revel, M. Buffoni and E.C. Borden. *Cytok. Cell. Mol. Ther.* 3, 27-32, 1997.
- Review Chapter: IFN-beta in the treatment of Multiple Sclerosis. M. Revel. *Pharmacology and Therapeutics*. Vol. 100, pp. 49-62, 2003.

D) Interferon-induced genes and cell responses

93. Interferon-dependent induction of mRNA activity for (2'-5') oligo-isoadenylate synthetase. Shulman L and Revel M. *Nature* 287: 98-100, 1980.
123. Interferon-induced 56,000-Mr protein and its mRNA in human cells: molecular cloning and partial sequence of the cDNA. Chebath J, Merlin G, Metz R, Benech P, Revel M. *Nucl. Acid Res.* 11, 1213-1226, 1983.
124. Molecular cDNA cloning and partial sequence of (2'-5') oligo A synthetase mRNA from human cells. Merlin G, Chebath J, Benech P, Metz R, Revel M. *Proc. Natl. Acad. Sci. USA* 80, 4904-4908, 1983.
135. Structure of two forms of the interferon-induced (2'-5') oligo A synthetase of human cells based on cDNA and gene sequences. Benech P, Mory Y, Revel M and Chebath J. *EMBO J.* 4: 2249-2256, 1985.
141. Four different forms of interferon-induced (2'-5') oligo A synthetase identified by immunoblotting in human cells. Chebath J, Benech P, Hovanessian, AG, Galabru J and Revel M. *J. Biol. Chem* 262: 3852-3857, 1987.
148. Interferon-responsive regulatory elements in the promoter of the human (2'-5') oligo (A) synthetase gene. Benech P, Vigneron M, Peretz D, Revel M and Chebath J. *Mol. Cell. Biol.* 7:4498-4504, 1987.
150. Constitutive expression of (2'-5') oligo A Synthetase confers resistance to picornavirus infection. J. Chebath, P. Benech, M. Revel and M. Vigneron. *Nature*, 330, 587-588, 1987.
185. The human Interferon α -Receptor protein confers differential responses to human Interferon- β versus Interferon- α subtypes in mouse and hamster cell transfectants. C. Abramovich, J. Chebath and M. Revel. *Cytokine*, 6, 414-424, 1994.
189. Differential tyrosine phosphorylation of the IFNAR1 chain of the type I Interferon receptor and of an associated surface protein in response to IFN- α and IFN- β . C. Abramovich, L.M. Shulman, E. Ratovitski, S. Harroch, M. Tovey, P. Eid and M. Revel. *EMBO J.*, 13, 5871-5877, 1994.
198. A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I Interferon receptor. C. Abramovich, B. Yakobson, J. Chebath and M. Revel. *EMBO J.*, 16, 260-266, 1997.
205. Involvement of Receptor-bound Protein Methyltransferase PRMT1 in Antiviral and Antiproliferative effects of Type I Interferons. L. Altschuler, J.-O. Wook, D. Gurari, J. Chebath and M. Revel. *J. Interferon Cytok. Res.*, 19, 189-195, 1998.

E) Interleukin-6 (IL-6/IFN- β 2)

94. Two interferon mRNAs in human fibroblasts: in vitro translation and E.coli cloning studies. J. Weissenbach, Y. Chernajovsky, M. Zeevi, L. Shulman, H. Soreq, U. Nir, D. Wallach, M. Perricaudet, P. Tiollais and M. Revel. *Proc. Natl. Acad. Sci. USA*, 77, 7152-7156, 1980.
139. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth stimulatory cytokines. A. Zilberstein, R. Ruggieri, J.H. Korn and M. Revel. *EMBO Journal*, 5, 2529-2537, 1986.
151. Growth inhibition of human Breast Carcinoma and Leukemia/Lymphoma cell lines by recombinant IFN-beta-2 (BSF-2/IL-6). L. Chen, Y. Mory, A. Zilberstein and M. Revel. *Proc. Natl. Acad. Sci. USA*, 85, 8037-8041, 1988.
153. Recombinant Interferon-beta-2 (Interleukin-6) induces myeloid differentiation. L. Chen, D. Novick, M. Rubinstein and M. Revel. *FEBS Lett.*, 239, 299-304, 1988.
161. Interferon-beta-2 (Interleukin-6) stimulates synthesis of Complement protein factor B and C3 in human skin fibroblasts. Y. Katz, M. Revel and R.C. Strunk. *Eur. J. Immunol.*, 19, 983-988, 1989.
164. Monoclonal antibodies for affinity purification of IL-6/IFN- β 2 and for neutralization of its biological activity. D. Novick, Z. Eshhar, M. Revel and Y. Mory. *Hybridoma*, 8, 561-567, 1989.

167. Purification of soluble cytokine receptors from normal urine by ligand affinity and immuno-affinity chromatography. D. Novick, H. Engelmann, D. Wallach, O. Leitner, M. Revel and M. Rubinstein. *J. Chromatography*, 510, 331-337, 1990.
171. Interleukin-6 induces the (2'-5') oligo A Synthetase gene in M1 cells through an effect on the Interferon-Responsive Enhancer. B. Cohen, Y. Gothelf, D. Vaiman, L. Chen, M. Revel and J. Chebath. *Cytokine*, 3, 83-91, 1991.
177. Enhancement of Interleukin-6 cytostatic effect on human breast carcinoma cells by soluble IL-6 Receptor from urine and reversion by monoclonal antibody. D. Novick, L.M. Shulman and M. Revel. *Cytokine*, 4, 6-11, 1992.
178. Antitumor effects of human rIL-6 on Acute Myeloid Leukemia in mice and in cell cultures. T. Givon, S. Slavin, N. Haran-Ghera, R. Michalevich and M. Revel. *BLOOD*, 79, 2392-2398, 1992.
179. IL-6 gene transfection into 3LL tumor cells suppresses the malignant phenotype and confers immuno-therapeutic competence against parental metastatic cells. A. Porgador, E. Tzehoval, A. Katz, E. Vadai, M. Revel, M. Feldman and L. Eisenbach. *Cancer Res.*, 52, 3679-3686, 1992.
180. Abrogation of B16 Melanoma Metastases by Long Term Low Dose IL-6 Therapy. . Katz, L.M. Shulman, A. Porgador, M. Revel, M. Feldman and L. Eisenbach. *J. Immunother.* 13, 98-109, 1993.
181. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL Lung carcinomas. A. Katz, L.M. Shulman, M. Revel, M. Feldman and L. Eisenbach. *Int. J. Cancer*, 53, 812-818, 1993.
182. Interleukin-6 inhibits the proliferation of B Chronic Lymphocytic Leukemia cells which is induced by Tumor Necrosis Factor- α , β . D. Aderka, Y. Maor, D. Novick, H. Engelmann, Y. Kahn, Y. Levo, D. Wallach and M. Revel. *BLOOD*, 81, 2076-2084, 1993.
183. Interleukin-6 activates and regulates transcription factors of the Interferon-Regulatory-Factor (IRF) family in M1 cells. S. Harroch, Y. Gothelf, N. Watanabe, M. Revel and J. Chebath. *J. Biol. Chem.*, 268, 9092-9097, 1993.
184. Inhibition of CT-26 murine colorectal adenocarcinoma growth in the rectum of mice treated with recombinant human Interleukin-6. M. Rabau, H. Kashtan, S. Baron, J. Yossiphov, Y. Skornick, M. Revel and A. Eisenthal. *J. Immunotherapy*, 15, 257-264, 1994.
187. Induction by Interleukin-6 of Interferon Regulatory Factor-1 (IRF-1) gene expression through the palindromic Interferon Response Element pIRE and cell-type dependent control of IRF-1 binding to DNA. S. Harroch, M. Revel and J. Chebath. *EMBO J.*, 13, 1942-1949, 1994.
188. Interleukin-6 signaling via four transcription factors binding palindromic enhancers of different genes. S. Harroch, M. Revel and J. Chebath. *J. Biol. Chem.*, 269, 26191-26195, 1994.
190. Potential use of Interleukin-6 in Bone Marrow transplantation: effects of recombinant human IL-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. T. Givon, M. Revel and S. Slavin. *Blood*, 83, 1690-1697, 1994.
- 192: Interleukin-6: Effects on tumor models in mice and on the cellular regulation of transcription factor IRF-1. M. Revel, A. Katz, L. Eisenbach, M. Feldman, N. Haran-Ghera, S. Harroch and J. Chebath. *Ann. NY Acad. Sci.*, 762, 342-356, 1995.
194. Epitope peptides from Interleukin-6 Receptor which inhibit the growth of human myeloma cells. H. Halimi, M. Eisenstein, J-W Oh, M. Revel and J. Chebath. *Eur. Cytok. Netw.*, 6, 135-143, 1995.
195. 5' upstream sequences of Myd88, an IL-6 primary response gene in M1 cells: detection of functional IRF-1 and Stat factors binding sites. *Nucl. Acid Res.*, 23, 3539-3546, 1995.
196. A soluble Interleukin-6 Receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. J-W Oh, M. Revel and J. Chebath. *Cytokine*, 8, 401-409, 1996.
199. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. J-W Oh, A. Katz, S. Harroch, L. Eisenbach, M. Revel and J. Chebath. *Oncogene*, 14, 569-577, 1997.

202. IL-6 Receptor-IL-6 fusion proteins with enhanced IL-6-type pleiotropic activities. J. Chebath, D. Fischer, A. Kumar, J.-W. Oh, O. Kolett, T. Lapidot, M. Fisher, S. Rose-John, A. Nagler, S. Slavin and M. Revel. *Eur. Cytok. Netw.*, 8, 359-365, 1997
203. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. I. Mendel, A. Katz, N. Kozak, A. Ben-Nun and M. Revel. *Eur. J. Immunol.* 28, 1727-1737, 1998.
204. Increased sensitivity of IL-6 Deficient mice to Carbon tetrachloride Hepatotoxicity and protection by an IL-6 Receptor –IL-6 Chimera. A. Katz, J. Chebath, J. Friedman and M. Revel. *Cytok. Cell. Mol. Ther.*, 4, 221-227, 1998.
206. The soluble IL-6 Receptor/IL-6 Fusion protein enhances in vitro maintenance and proliferation of human CD34+CD38-/low cells capable of repopulating severe combined immuno-deficiency (SCID) mice. O. Kollet, R. Aviram, J. Chebath, H. ben-Hur, A. Nagler, L. Shultz, M. Revel, and T. Lapidot. *Blood*, 94, 923-931, 1999.
208. In vitro effects of recombinant Tumor Necrosis Factor- α binding protein (rTBP-1) on the hematopoiesis of HIV-infected patients. S. Gradstein, T. Hahn. Y. Barak, L. Malach, M. Revel, Z. Bentwich and Z.T. Handzel. *J. AIDS*, 26, 111-117, 2001.

F) IL-6 and IL-6 Chimera: differentiation of nerve myelination cells - Embryonic Stem Cells

207. Induction of myelin gene expression in Schwann cell cultures by an interleukin-6 receptor interleukin-6 chimera. S. Haggiag. J. Chebath and M. Revel. *FEBS Letters* 457, 200-204, 1999.
209. Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by Interleukin-6 receptor – Interleukin-6 chimera. S. Haggiag, P.-L. Zhang, G. Slutsky, V. Shinder, A. Kumar, J. Chebath and M. Revel., *J. Neuroscience Res.*, 64, 564-574, 2001.
210. Pax-3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by Interleukin-6 receptor signalling. A. Kumar Kamaraju , C. Bertolotto, J. Chebath and M. Revel. *J. Biol. Chem.* 277, 15132-15141, 2002.
211. Activation of Myelin genes during transdifferentiation from melanoma to glial cell phenotype. S. G. Slutsky, A. Kumar Kamaraju, A. Levy, J. Chebath and M. Revel. *J. Biol. Chem.* 278 , 8960-8968, 2003.
212. HGF, SDF-1 and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. O. Kollet, [...], M. Revel, D.A. Shafritz and T. Lapidot. *J. Clin. Invest.* 112, 160-169, 2003.
213. C/EBP- δ induction by gp130 signaling: role in transition to myelin gene expression phenotype in a melanoma cell line model. A. Kumar Kamaraju, S. Adjalley, P.L. Zhang, J. Chebath and M. Revel. *J. Biol. Chem.* 279, 3852-3861, 2004.
214. Enhancement of oligodendrocyte differentiation from murine embryonic stem (ES) cells by an activator of gp130 signaling. P.L. Zhang, J. Chebath, P. Lonai and M. Revel. *STEM CELLS*, 22, 344-354, 2004.
215. Increased myelination capacity of embryonic stem cell derived oligodendrocyte precursors after treatment by interleukin-6/soluble interleukin-6 receptor fusion protein. P.L. Zhang, M. Izrael, E. Ainfinder, L. Ben-Simchon, J. Chebath and M. Revel. *Mol. Cell. Neurosci.*, 31, 387-398, 2006.
216. Human oligodendrocytes derived from embryonic stem cells: effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. M. Izrael, P.L. Zhang, R. Kaufman, V. Shinder, R. Ella, M. Amit, J. Itskovitz-Eldor, J. Chebath and M. Revel. *Mol. Cell. Neurosci.*, 34, 310-323, 2007.
217. Human oligodendrocytes produced from embryonic stem cells. P.L. Zhang, M. Izrael, R. Kaufman, M. Amit, J. Itskovitz-Eldor and M. Revel. In: *Glial Cells in Health and Disease, The VIII European Meeting, September 4-8, 2007, Medimond International Proceedings H904C0445*, 2007.
218. Induction of neuronal and myelin-related gene expression by IL-6-receptor/IL-6: A study on embryonic dorsal root ganglia cells and isolated Schwann cells. Pei-Lin Zhang , Alon M. Levy ,

Levana Ben-Simchon, Shalom Haggiag, Judith Chebath, Michel Revel. *Experimental Neurology* 208, 285–296, 2007.

- 219.** Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity. Noelle Callizot, Emile Andriambeloson, Jonathan Glass, Michel Revel, Pamela Ferro, Rocco Cirillo, Pierre-Alain Vitte, Michel Dreano. *Cancer Chemother. Pharmacol.* 62, 995-1007, 2008.
- 220.** Survival, differentiation, and reversal of heroin neurobehavioral teratogenicity in mice by transplanted neural stem cells derived from embryonic stem cells. Meital Kazma, Michal Izrael, Michel Revel, Judith Chebath, and Joseph Yanai. *J Neurosci Res.* 88:315-23, 2010
- 221** Suspension culture of undifferentiated human embryonic and induced pluripotent stem cells. Michal Amit, Judith Chebath, Victoria Margulets, Ilana Laevsky, Yael Miropolsky, Kohava Shariki, Meital Peri, Idit Blais, Guy Slutsky, Michel Revel and Joseph Itskovitz-Eldor. *Stem Cell Rev and Rep.* 6, 248-259, 2010
- 222. Compact MRI for the detection of teratoma development following intrathecal human embryonic stem cell injection in NOD-SCID mice.** Ramot Y, Schiffenbauer YS, Amouyal N, Ezov N, Steiner M, Izrael M, Lavon N, Hasson A, Revel M, Nyska A. *Neurotoxicology.* 59, 27-32, 2017.
- 223. Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1^{G93A} and NSG animal models.** Michal Izrael, Shalom Guy Slutzky, Tamar Admon, Louisa Cohen, Avital Granit, Arik Hasson, Joseph Itskovitz-Eldor, Lena Krush Paker, Graciela Kuperstein, Neta Lavon, Shiran Yehezkel Ionescu, Leonardo Javier Solmesky, Rachel Zaguri, Alina Zhuravlev, Ella Volman, Judith Chebath and Michel Revel. *Stem Cell Research & Therapy* 9, 152-169, 2018
- 224. Rising Stars: Astrocytes as a Therapeutic Target for ALS Disease.** Izrael M, Slutsky SG, Revel M. *Front Neurosci.* 2020 Jul 28;14:824. doi: 10.3389/fnins.2020.00824. PMID: 32848579; PMCID: PMC7399224.
- 225. Selection for CD26- and CD49A+ Cells From Pluripotent Stem Cells-Derived Islet-Like Clusters Improves Therapeutic Activity in Diabetic Mice.** Molakandov K, Berti DA, Beck A, Elhanani O, Walker MD, Soen Y, Yavriyants K, Zimmerman M, Volman E, Toledo I, Erukhimovich A, Levy AM, Hasson A, Itskovitz-Eldor J, Chebath J, Revel M. *Front Endocrinol (Lausanne).* 2021 May 5;12:635405. doi: 10.3389/fendo.2021.635405. PMID: 34025576; PMCID: PMC8131825.
- 226. Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19.** Izrael M, Molakandov K, Revel A, Slutsky SG, Sonnenfeld T, Weiss JM, Revel M. *Front Med (Lausanne).* 2021 Oct 29;8:740071. doi: 10.3389/fmed.2021.740071. PMID: 34778302; PMCID:PMC8585990.

Selected Books and Reviews - Prof. Michel Revel

- Book: Atlas de Biologie Moleculaire, M. Herzberg and M. Revel. Editions Hermann, Paris, 1972
- Book: Clinical Aspects of Interferons. Michel Revel, Editor. Kluwer Academic Publ., Boston, 1988..
- Book: IL-6 Physiopathology and clinical potentials. M. Revel, editor. Sero Symposia, Vol 88, Raven Press, New York, 1992.
- Review Chapter: Post-transcriptional and translational controls of gene expression in eukaryotes. Revel M and Groner Y. Annual Review of Biochemistry 47: 1079-1126, 1978.
- Review Chapter: Interferon-activated genes. M. Revel and J. Chebath. Trends in Biochemical Sciences, 11, 166-170, 1986.
- Review Chapter: Host defense against infections and inflammations: Role of the multifunctional IL-6/IFN-beta-2 cytokine. M. Revel. Experientia, 45, 549-557, 1989.
- Review Chapter: Antitumor potential of Interleukin-6. Interferon and Cytokines, 19, 5-8, 1991.
- Review Chapter: Growth regulatory functions of IL-6 and antitumor effects. M. Revel. in Forum in Immunology: Forum on IL-6. Research in Immunol. 143, 769-773, 1992.
- Review Chapter: The 2'-5' A System: 2'-5' A Synthetases, isospecies and functions. J. Chebath and M. Revel. in Interferon, principles and medical applications. S. Baron et al (eds), University of Texas Medical Branch at Galveston, TX, pp 225-236, 1992..
- Review Chapter: Treatment of Cervical Intraepithelial Neoplasia and Invasive Squamous Cell Carcinoma by Interferon. J. Bornstein, Y. Ben-David, J. Atad, B. Pascal and H. Abramovici. Obstetrical and Gynecological Survey, 48, 251-260, 1993.
- Review Chapter: Glycosylated Interferon-beta in Multiple Sclerosis. M. Revel and P. Kalinka In: Frontiers in Multiple Sclerosis. Clinical Research and Therapy. O. Amramsky, H. Ovadia (eds). Martin Dunitz Publ., pp. 243-254, 1997.
- Review Chapter: Interferon-beta: Structure, Differential actions and Medical applications. M. Revel. In: Growth Factors and Cytokines in Health and Disease. D. LeRoith, C. Bondy (eds), JAI Press Inc. Volume 2B, pp 433-520, 1997.
- Review Chapter: IFN-beta in the treatment of Multiple Sclerosis. M. Revel. Pharmacology and Therapeutics. Vol. 100, pp. 49-62, 2003.

Selected BIOETHICS articles: Michel Revel

Report on Genetic Counselling, Proc. UNESCO International Bioethics Committee, 1996

An outright, upfront condemnation of cloning research is premature. The Scientist, 12, 38, 1998

L'éthique ne doit pas interdire d'emblée. La Croix, March 1999.

Ongoing research on Mammalian cloning and Embryo Stem Cell technologies: Bioethics of their potential Medical Applications. Israel Medical Assoc. Journal 2, suppl: 8-14, 2000

Report on Human Embryo Stem Cell Research. UNESCO International Bioethics Committee, 2001.

Report on Human Embryo Stem Cell Research in Israel. Bioethics Committee of the Israel Academy of Science and Humanities (as chair), 2001.

Ashes from a stolen flame (on Prometheus). M. Revel. Haaretz, 4 May 2001.

Report on Population-based Large-Scale Collections of DNA Samples and Databases of Genetic Information. Bioethics Committee of the Israel Academy of Science and Humanities (as chair), 2002.

Pour un clonage reproductif humain maîtrisé. M. Revel. Le Monde, 4 Janvier 2003.

Demain les clones. M. Revel,. Liberation, 27 Fevrier 2003.

Human Reproductive Cloning, Embryo Stem Cells and Germline Gene Intervention: An Israeli Perspective. M. Revel. Medicine and Law, 22, 701-732, 2003.

Science, Ethics and Arms of Mass Destructions (Hebrew). M. Revel. Academia 12, 4-7, 2003.

The Ethical Issues raised by Behavioral Genetics in Humans. M. Revel. Proceedings of the International Bioethics Committee, Unesco, 9th session, Vol II, 81-94, Unesco Publications 2003.

Are Genes Our Destiny? - Implications and Ethical limitations of Genetic Determinism in Medicine and Behavioural Sciences. M. Revel. In: The Embryo: Scientific Discovery and Medical Ethics, S. Blazer, E.Z. Zimmer eds., Karger Pub., Basel, 2005, pp143-165.

Ethical issues of Human Embryo cloning technologies for Stem Cell research. M. Revel. In: The Embryo: Scientific Discovery and Medical Ethics, S. Blazer, E.Z. Zimmer eds., Karger Pub., Basel, 2005, pp107-119.

UNESCO Universal Declaration on Bioethics and Human Rights: Why there is a need to take Cultural Diversity into account. M. Revel, Proceedings of the International Bioethics Committee, Unesco, 12th session, Unesco Publications, 2005.

Research on Human Embryonic Stem cells and cloning for Stem Cells. M. Revel. Human Reproduction and Genetic Ethics. Vol 14, 4-14, 2008.